Stroke Diagnostic Presentation at EuroMedLab 2017 – Research Milestone Achieved
We are pleased to announce that Randox Laboratories Ltd, (“Randox”) presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this month. This is a novel diagnostic test designed to improve the clinical management of stroke and is based on multiple biomarkers some of which have been licensed from Proteome Sciences and developed in association with the Biomedical Proteomics Research Group at the University of Geneva.
New Registered Address
Proteome Sciences plc (AIM:PRM) is pleased to announce that its corporate headquarters have moved from Cobham to new premises in central London.
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 10 May 2017 it purchased 97,314 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,443,715 equivalent to 18.48% of Proteome Sciences' total issued share capital.
Director/PDMR Shareholding
Following the Purchases Vulpes has a total direct and indirect interest in 54,346,401 equivalent to 18.44% of Proteome Sciences' total issued share capital. The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that it has made the following purchases of ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") (the “Purchases”):
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 1,329 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 4.9p per Ordinary Share (the “First Purchase”). The Company has also received notification that on 03 May 2017 Vulpes purchased a further 240 Ordinary Shares at a price of 4.85p per Ordinary Share (the “Second Purchase”) (together with the First Purchase, “the Purchases”). Following the Purchases Vulpes has a total direct and indirect interest in 54,145,284 equivalent to 18.38% of Proteome Sciences' total issued share capital.
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,143,715 equivalent to 18.37% of Proteome Sciences' total issued share capital.
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 27 April 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares" and the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,043,715 equivalent to 18.34% of Proteome Sciences' total issued share capital.
AGM Statement and Result of AGM
At the Company’s AGM held today the Chairman, Christopher Pearce, made the following statement: “As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences. The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations.”
Director Dealing and Total Voting Rights
Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) respectively.
Option Awards
The Options represent 6.17% of the current issued share capital of the Company and lapse on 3 April 2027.